[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-motor-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-motor-symptoms":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100602088","respiratory-gated-transcutaneous-auricular-vagus-nerve-stimulation-for-improving-apathy-in-parkinsons-disease-100602088",false,"NCT07118956","Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease","Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease: A Randomized, Double-blind, Sham-controlled Trial","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for idiopathic Parkinson's disease (based on the MDS Clinical Diagnostic Criteria for Parkinson's Disease (2015 version)).\n2. Patients with Apathy Motivation Index (AMI) score \\>1.7.\n3. All PD patients must be on stable, standardized medication regimens with no adjustments to medications for at least 1 month prior to the study and throughout the study period.\n4. Demonstrate good compliance and adherence, capable of completing behavioral tests and taVNS therapy.\n5. Mini-Mental State Examination (MMSE) score ≥22.\n6. Meet safety criteria for MRI screening.\n\nExclusion Criteria:\n\n1. Prior brain MRI\u002FCT showing focal brain lesions or severe white matter disease (Fazekas grade 3 or higher).\n2. Secondary parkinsonism (e.g., vascular parkinsonism, drug-induced parkinsonism).\n3. History of severe traumatic brain injury, neurosurgery, or deep brain stimulation (DBS) therapy.\n4. Personal history of epilepsy, unexplained loss of consciousness, or current use of anticonvulsant medications for seizure control.\n5. Diagnosis of neuropsychiatric disorders other than Parkinson's disease.\n6. Current use of non-steroidal anti-inflammatory drugs (NSAIDs) or Non-benzodiazepine GABA receptor agonist drug or anticholinergics or corticosteroids, or history of substance abuse or drug addiction.\n7. Participation in any clinical trial within the past 3 months.\n8. Severe systemic comorbidities (e.g., hepatic\u002Frenal failure, arrhythmias, organic heart disease).\n9. Pregnant\u002Flactating women or subjects (including males) planning pregnancy within 6 months.\n10. Contraindications to taVNS, such as cardiac pacemakers, post-DBS surgery, or auricular pathologies (e.g., tympanic membrane perforation).","ALL","40 Years","90 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether 100HZ respiratory-gated vagus nerve stimulation (RAVANS) can improve the non-motor symptoms in people with Parkinson's disease (PD). It will also learn the safety of 100HZ RAVANS. The main questions it aims to answer are:\n\nCan 100HZ RAVANS improve apathy in people with PD? Did the participants have any side effects or safety issues when undergoing 100HZ RAVANS? Researchers compared 100HZ RAVANS with sham stimulation (low-dose stimulation of the same site and treatment parameters) to see if 100HZ RAVANS could improve non-motor symptoms in patients with PD.\n\nParticipants will:\n\nReceive 100HZ RAVANS or sham stimulation for 2 weeks. Neuropsychological assessment, imaging and biological sample collection were conducted before and after the entire cycle.",[27,28,29,30],"Parkinson Disease","Apathy","Non-motor Symptoms","Vagus Nerve Stimulation",[27,28,32,33],"Non-motor symptoms","Transcutaneous Auricular Vagus Nerve Stimulation","RECRUITING","2025-11-17",{"date":37,"type":38},"2025-11-19","ACTUAL",{"date":40,"type":38},"2025-05-01",{"date":42,"type":21},"2028-05-01",{"name":44,"class":45},"Anhui Medical University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100390659","international-validation-of-two-non-motor-scales-in-pd-nfs-and-spark-100390659","NCT04366804","International Validation of Two Non-motor Scales in PD (NFS and SPARK)","International Validation of Two Non-motor Scales in Parkinson's Disease: the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in Parkinson's Disease (SPARK) Scale","Inclusion Criteria:\n\n1. Written informed consent;\n2. PD, according to the MDS criteria;\n3. Age of participants \\> 30 and \\\u003C 75 years;\n4. Being fluent in the language in which the scales are applied.\n\nExclusion Criteria:\n\n1\\. Presence of PD dementia (defined as MoCA score \\\u003C 24).","30 Years","75 Years",{"count":57,"type":21},300,"OBSERVATIONAL","The goal of this project is to develop the international validation of two new rating scales, the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale, in order to improve the understanding of the extent and severity of non-motor symptoms in Parkinson's disease (PD).",[61,29],"Parkinson's Disease",[61,32,63,64],"Scales for non-motor symptoms","Validation","2025-04-09",{"date":67,"type":38},"2025-04-13",{"date":69,"type":38},"2020-12-03",{"date":71,"type":21},"2025-12-31",{"name":73,"class":45},"Insel Gruppe AG, University Hospital Bern",8,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":55,"enrollmentInfo":82,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100512954","study-on-brain-network-mechanism-of-deep-brain-stimulation-for-parkinsons-disease-100512954","NCT05959161","Study on Brain Network Mechanism of Deep Brain Stimulation for Parkinson's Disease","Study on Brain Network Mechanism of Deep Brain Stimulation for Parkinson's （A Retrospective Study）","Inclusion Criteria:The clinical diagnosis of PD is consistent with the United Kingdom Parkinson's Disease Society Brain Bank criteria, with disease duration over 5 years, age under 75, acute levodopa motor response ≥30%, and indication for STN-DBS. -\n\nExclusion Criteria: patients with severe cognitive impairment, severe psychiatric disorders, acute levodopa motor response less than 30%, atypical parkinsonism, and contraindications to surgery -",{"count":83,"type":21},100,"As a surgical intervention, DBS can effectively relieve PD tremor, rigidity, bradykinesia and other symptoms. How to better screen patients suitable for DBS treatment and conduct reasonable preoperative and postoperative evaluation is crucial to judge the treatment effect and prognosis. The clinical symptom evaluation of PD patients can be divided into motor symptom evaluation and non-motor symptom evaluation. The motor symptoms of PD patients were evaluated by UPDRS III. The evaluation of non-motor symptoms in PD patients was mainly divided into three aspects: cognitive status, emotional status, and sleep status. Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used to assess the cognitive status of PD patients. The Hamilton Depression Scale (HAMD) was used to assess the patients' depression status. The Hamilton Anxiety Scale (HAMA) was used to assess the patients' anxiety status. The PD Sleep Scale 2nd version, The PD Sleep Scale 2nd version, PDSS - 2), and rem Sleep Behavior Disorder Questionnaire (sweet HK) (Rapid Eye Movement Sleep behaviors Disorder Questionnaire - Hong Kong, RBDQ - HK) to assess Sleep conditions.",[27,86,29],"Deep Brain Stimulation","NOT_YET_RECRUITING","2023-07-17",{"date":90,"type":38},"2023-07-25",{"date":92,"type":21},"2023-08-01",{"date":94,"type":21},"2026-12-31",{"name":96,"class":45},"Tianjin Huanhu Hospital"]